Methotrexate Dose Has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial

June 2013 in “ Annals of the rheumatic diseases ”

Gerd R. Burmester, A. Kivitz, Ronald F. van Vollenhoven, S. Florentinus, P.M. Karunaratne, H. Küpper, Maxime Dougados, Roy Fleischmann

methotrexate adalimumab hair loss rheumatoid arthritis MTX ADA

TLDR Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.

The CONCERTO trial evaluated the dose-response of methotrexate (MTX)-related toxicities in patients with early rheumatoid arthritis treated with adalimumab (ADA) and varying doses of MTX (2.5, 5, 10, or 20 mg). The study included 395 patients, with 358 completing the 26-week trial. The overall incidence of MTX-related adverse events (AEs) was low, though some AEs, such as infection and abnormal hair loss, appeared to increase with higher MTX doses. No significant differences were observed in hematologic or liver enzyme changes among the different MTX doses. The findings suggested that the lowest effective MTX dose in combination with ADA might be preferable to minimize AEs.

View this study on ard.bmj.com →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Patient’s Experience with Subcutaneous and Oral Methotrexate for the Treatment of Rheumatoid Arthritis

23 citations, September 2016 in “BMC musculoskeletal disorders”

Methotrexate for rheumatoid arthritis often causes side effects like diarrhea, fatigue, and hair loss, especially at higher doses.

research Baricitinib: From Rheumatoid Arthritis to COVID-19

42 citations, April 2021 in “Journal of clinical pharmacology”

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review

February 2024 in “PloS one”

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

research Treatments for Dissecting Cellulitis of the Scalp: A Systematic Review and Treatment Algorithm

1 citations, September 2023 in “Dermatology and therapy”

More research is needed to find the best treatment for dissecting cellulitis of the scalp.

research Comprehensive Overview of Rheumatology Studies: Ottawa, Ontario, Canada, February 13–16, 2013

4 citations, June 2013 in “The Journal of Rheumatology”

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.